Literature DB >> 23992099

Proteus syndrome review: molecular, clinical, and pathologic features.

M Michael Cohen1.   

Abstract

Proteus syndrome is caused by an activating AKT1 mutation (c.49G>A, p.Glu17Lys). Many variable features are possible in this mosaic disorder, including: (i) disproportionate, asymmetric, and distorting overgrowth; (ii) bone abnormalities different from those observed in other disorders; (iii) a characteristic cerebriform connective tissue nevus made up of highly collagenized connective tissue; (iv) epidermal nevi in early life, consisting of acanthosis and hyperkeratosis; (v) vascular malformations of the capillary, venous, or lymphatic types; (vi) dysregulated adipose tissue including lipomas, lipohypoplasia, fatty overgrowth, and localized fat deposits; (vii) other unusual features, including bullous lung alterations; specific neoplasms; a facial phenotype associated with intellectual disability and/or seizures, and/or brain malformations; and (viii) deep vein thrombosis, resulting in premature death. Concluding remarks address diagnostic criteria, natural history, management, psychosocial issues, and differential diagnosis.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  AKT1 mutation; Joseph Merrick; bullous lung alterations; cerebriform connective tissue nevus; deep vein thrombosis; diagnostic criteria; differential diagnosis; disproportionate overgrowth; dysregulated adipose tissue; epidermal nevus; management; natural history; psychosocial issues; skeletal anomalies; unusual neoplasms; vascular malformations

Mesh:

Substances:

Year:  2013        PMID: 23992099     DOI: 10.1111/cge.12266

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  31 in total

Review 1.  Approach to the Diagnosis of Overgrowth Syndromes.

Authors:  Mohnish Suri
Journal:  Indian J Pediatr       Date:  2015-12-18       Impact factor: 1.967

Review 2.  Diffuse Cystic Lung Disease. Part II.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-07-01       Impact factor: 21.405

Review 3.  Neurocutaneous Manifestations of Genetic Mosaicism.

Authors:  Maurice A M van Steensel
Journal:  J Pediatr Genet       Date:  2015-11-30

Review 4.  Overgrowth Syndromes.

Authors:  Andrew C Edmondson; Jennifer M Kalish
Journal:  J Pediatr Genet       Date:  2015-09-25

5.  Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.

Authors:  Seung-Hyun Jung; Min Sung Kim; Sung-Hak Lee; Hyun-Chun Park; Hyun Joo Choi; Leeso Maeng; Ki Ouk Min; Jeana Kim; Tae In Park; Ok Ran Shin; Tae-Jung Kim; Haidong Xu; Kyo Young Lee; Tae-Min Kim; Sang Yong Song; Charles Lee; Yeun-Jun Chung; Sug Hyung Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

Review 6.  Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.

Authors:  Arno E Commandeur; Aaron K Styer; Jose M Teixeira
Journal:  Hum Reprod Update       Date:  2015-07-03       Impact factor: 15.610

7.  Nasopharyngeal angiofibroma in an adult with Proteus syndrome. First reported case.

Authors:  A Delides; J G Panayiotides; A Kaberos; I Giotakis
Journal:  Hippokratia       Date:  2017 Jul-Sep       Impact factor: 0.471

8.  Myocardial fat overgrowth in Proteus syndrome.

Authors:  H Hannoush; V Sachdev; A Brofferio; A E Arai; G LaRocca; J Sapp; S Sidenko; C Brenneman; L G Biesecker; K M Keppler-Noreuil
Journal:  Am J Med Genet A       Date:  2014-11-06       Impact factor: 2.802

9.  Proteus syndrome caused by novel somatic AKT1 duplication.

Authors:  Talal AlAnzi; Eman Al-Mashharawi; Amal Alhashem
Journal:  Saudi Med J       Date:  2021-01       Impact factor: 1.484

Review 10.  Somatic mosaicism: implications for disease and transmission genetics.

Authors:  Ian M Campbell; Chad A Shaw; Pawel Stankiewicz; James R Lupski
Journal:  Trends Genet       Date:  2015-04-21       Impact factor: 11.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.